MANNKIND CORP (MNKD)
US56400P7069 - Common Stock
MNKD Makes Notable Cross Below Critical Moving Average
MannKind Repays Certain Debt Obligations
MannKind Repays Certain Debt Obligations
Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 millionConvertible note issued to Mann Group LLC repaid in...
May 10th Options Now Available For MannKind (MNKD)
MannKind Announces CFO Transition
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
INHALE-3 STUDY’S INITIAL MEAL CHALLENGE RESULTS COMPARING AFREZZA® HEAD-TO-HEAD WITH MULTIPLE DAILY INJECTIONS (MDI) AND INSULIN PUMPS ...
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
Dr. Hirsch to present meal challenge results when switching from multiple daily injections (MDI) or insulin pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder)
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
Dr. Hirsch to present meal challenge results when switching from multiple daily injections (MDI) or insulin pumps to inhaled insulin (Afrezza® (insulin...
MannKind Corporation Announces Participation at Upcoming Conferences
MannKind Corporation Announces Participation at Upcoming Conferences
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development...
MannKind (MNKD) Q4 2023 Earnings Call Transcript
MNKD earnings call for the period ending December 31, 2023.
MannKind Non-GAAP EPS of $0.02 beats by $0.03, revenue of $58.47M beats by $5.33M (NASDAQ:MNKD)
MannKind Corporation's Q4 financial results exceeded expectations with non-GAAP EPS of $0.02, beating estimates by $0.03, and revenue of $58.47M, surpassing...
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
Conference Call to Begin Today at 5:00 p.m. (ET)
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
Conference Call to Begin Today at 5:00 p.m. (ET)...
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 fourth quarter...
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
MANNKIND ANNOUNCES ENROLLMENT GOAL COMPLETION OF INHALE-1 PEDIATRIC DIABETES TRIAL UTILIZING AFREZZA...
Commit To Purchase MannKind At $2.50, Earn 10.6% Annualized Using Options
3 Biotech Stocks to Sell in January Before They Crash and Burn
The biotech industry is one of the most profitable though risky at the same time. Here are three biotech stocks to sell.
KNDI, IREN and om are among after hour movers (NASDAQ:MNKD)
Gainers: MannKind Corporation (NASDAQ:MNKD) +5%.Kandi Technologies Group (KNDI) +5%.Outset Medical (OM) +4%.HWH International (HWH) +3%.Atea Pharmaceuticals...
Notable Tuesday Option Activity: SMCI, MRK, MNKD
MannKind, Sagard Healthcare enter $200M royalty purchase deal (NASDAQ:MNKD)
MannKind (MNKD) sells a 1% royalty in Tyvaso DPI net sales to Sagard Healthcare for up to $200M, receiving an upfront payment of $150M.
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
Sagard Healthcare purchased a 1% royalty in Tyvaso DPI® net salesPurchase price of $150 million; additional potential milestone payment of up to $50...
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development...
High-Yield Haven: 3 Dividend Stocks to Secure Now
These are three different dividend stocks that have a great dividend yield and offer a reliable source of income.
Commit To Purchase MannKind At $2.50, Earn 6% Using Options
MannKind (MNKD) Q3 2023 Earnings Call Transcript
MNKD earnings call for the period ending September 30, 2023.